Introduction
============

Breast cancer is a major public health problem in women throughout the world. In 2008, it was the most common cause of death in women (458,000 deaths) worldwide \[[@B1]\]. Breast cancer is also the most common cancer and the fifth cause of mortality due to malignancies among Iranian women \[[@B1],[@B2]\].

The human mitochondrial genome consists of a circular double-stranded DNA of 16,569 base pairs, including genes encoding for the electron transport chain (complexes I-IV), ATP synthase or complex V in oxidative phosphorylation as well as a displacement loop region, 2 ribosomal RNAs (16 and 23) and 22 transfer RNAs \[[@B3],[@B4]\]. Variants of *ATPase subunit 6* (8366--8572) and *ATPase subunit 8* (8527--9207) in mitochondrial DNA (mtDNA) has been reported in different types of cancers, including breast, colon and ovarian \[[@B5]-[@B7]\].

The mitochondrion plays a critical role in cellular energy production \[[@B8]\], carcinogenesis and tumor progression, and could be a prognostic marker in different cancer types \[[@B5],[@B9]-[@B15]\]. To date, various types of mtDNA alterations, including point variants, large deletion and copy number changes have been reported in breast, colon and ovarian cancers \[[@B5],[@B16]\]. There is strong evidence that mtDNA alterations can enhance oxidative stress and the risk of tumor development as well as tumor initiation, proliferation \[[@B17]\], metastasis \[[@B18]-[@B20]\] and resistance of cancer cells to apoptosis \[[@B21]\].

Therefore, this study was undertaken to evaluate mitochondrial *ATPase6* and *8* alterations in tumor and adjacent non-tumor tissues in breast cancer patients. We also investigated the correlation between the variants in these genes and the clinico-pathological features in these breast cancer patients.

Materials and Methods
=====================

Tumor tissue collection
-----------------------

Forty-nine breast cancer patients (34--75 years of age with a median age of 52.43 years) took part in this study. The patients were referred to the National Cancer Institute (NCI) at Imam Khomeini Hospital Complex, Tehran, Iran, from Oct. 2007 to Oct. 2009. Tumor tissue and adjacent non-tumor tissue samples were obtained from the Iranian National Tumor Bank (INTB) at NCI. Each specimen was immediately frozen following resection and stored at −80°C until DNA extraction. The pathologic changes in tumor samples were confirmed by two expert pathologists as adenocarcinomas according to the American Joint Committee on Cancer \[[@B22]\]. None of the patients received chemotherapy or radiotherapy treatment before they underwent surgery. All patients were informed on the aim of the study and signed an informed consent approved by the INTB Ethical Committee for the genetic analysis.

DNA extraction and PCR
----------------------

In order to identify the alterations in the mtDNA *ATPase6* and *ATPase8* genes, PCR-sequencing was performed as described previously with some modifications \[[@B23]\] Total genomic DNA was extracted from fresh tumor samples containing at least 90% neoplastic cells, as well as their adjacent non-tumor tissues, using the QIAamp Mini Kit (USA). The sequences of the primers were as follows: F-ATPase: 5′- CTACGGTCAATGCTCTGAAA -3′ (Accession No. NC_012920.1, 8161--8180). R-ATPase: 5′-TACTATATGATAGGCATGTGA-3′ (9219--9239). PCR amplification was performed using a ready-to-use PCR master mix (Sinaclon LTD, Tehran, Iran) in a final volume of 50 μl containing 5 ng of genomic DNA and 0.10 μM of each primer in a MJ Mini Gradient Thermal Cycler PTC-1148 (Bio-Rad, USA). PCR amplification was carried out with the following program: a 5-min pre-PCR incubation step at 95°C, 35 cycles of 95°C for 60 s, annealing temperature at 55°C for 1 min and 72°C for 2 min, and a final extension of 72°C for 10 min. The amplified fragment (1078 bp) was observed on 1.5% agarose gel.

Sequencing analysis
-------------------

The PCR products were sequenced using the previously reported primers \[[@B23]\] on a ABI Prism 3700 automated sequencer (Applied Biosystems, USA). Sequence analysis was carried out using the FinchTV 1.4 software (Geospiza, Inc., USA). The sequences were compared to the human mtDNA reference sequence (Gene Bank ID: NC_012920.1) using the BLAST sequence analysis tool (NCBI, Bethesda, USA). The Mitomap database was used to identify mitochondrial genome sequence variants.

Prediction of pathogenicity by protein modeling analysis
--------------------------------------------------------

The impact of non-synonymous (coding) substitutions in the resulting protein was assessed using PolyPhen-2 (v. 2.2.2) software, a tool for predicting the possible impact of an amino acid substitution variant on the structure and function of the corresponding protein, which is interpreted as benign and damaging effects \[[@B24]\].

Statistical analysis
--------------------

The correlation between each alteration in the *ATPase6* and *ATPase8* genes in tumor samples and their adjacent normal tissue were analyzed by Fisher's exact test using statistical package SPSS (v.16.1). The correlation between the groups was considered statistically significant if the *p-*value was less than 0.05. Additionally, for each variant the odds ratio (OR) and 95% confidence interval (95% CI) were calculated in order to determine its association to the increased risk in breast cancer patients. The association between mtDNA alteration and clinico-pathological characteristics of breast cancer patients with more than one missense mutation was evaluated using One-way ANOVA analysis.

Results
=======

In this study, the complete sequences of the *ATPase6* and *8* genes of 49 tumor tissues and adjacent non-tumor tissues were analyzed in a cohort of breast cancer patients. The clinico-pathological characteristics of the patients are summarized in Table [1](#T1){ref-type="table"}. From 49 breast cancer cases, 28 mtDNA variants were found in tumor tissues, which were not present in their adjacent normal tissues. From 28 variants, 23 (82.14%) were found in the *ATPase6* gene and the remaining 5 sequence variants were detected in the *ATPase8* gene. All cases showed variants in the *ATPase6* gene, whereas only 8.16% (4 of 49) cases had variants in the *ATPase8* gene. Among 28 mtDNA alterations, 26 were at the homoplasmic state and the remaining 2 variants were at the heteroplasmic state (Table [2](#T2){ref-type="table"}). However, there was no significant correlation (*P* \> 0.05) between the *ATPase6* and *8* gene variants and the clinico-pathological characteristics of the patients (Table [1](#T1){ref-type="table"}). Our results indicated that the A8860G variant was detected in 100% of tumor tissue samples compared to adjacent non-tumor tissues, showing that this alteration may significantly increase breast cancer risk (*P* \< 0.05). However, the patients' survival was shorter in cases with more than one mtDNA non-synomous *ATPase* variant compared to the patients with only one mtDNA non-synonymous *ATPase* variant (A8860G ) (*p* =0.051, Table [1](#T1){ref-type="table"}).

###### 

**Characterization of clinico-pathological parameters and the frequency of cases with more than one somatic mtDNA (*ATPase6/8*) mutation in breast cancer patients**

   **Frequency of patients in each group**   **Patients with more than one somatic mtDNA (*ATPase6/8*) mutation**                                    
  ----------------------------------------- ---------------------------------------------------------------------- ----------- --------------------- -------------
                **Variable**                                              **n (%)**                                 **n (%)**   **OR; (95% CI)\***    **P value**
        **Total number of patients**                                          49                                                                            
         **Age at diagnosis (Yrs)**                                                                                             1.482(0.403-5.451)       0.746
                    \<50                                                   19(42.2)                                  5(26.3)                                
                     ≥50                                                   26(57.8)                                  9(34.3)                                
           **Histological grade**                                                                                                                        0.121
                      I                                                    13(29.5)                                  1(7.7)                                 
                     II                                                   24 (54.5)                                  9(37.5)                                
                     III                                                   7(15.9)                                   3(42.9)                                
             **TNM(AJCC) stage**                                                                                                                         0.680
                      I                                                     3(6.7)                                   1(33.3)                                
                     II                                                    10(22.2)                                  2(20.)                                 
                     III                                                    3(6.7)                                    0(0)                                  
                     IV                                                    (64.4)29                                 11(37.9)                                
             **Tumor size(cm)**                                                                                                                          0.889
                     \<2                                                   5(11.1)                                    2(40)                                 
                     2-5                                                   30(66.7)                                   9(30)                                 
                     \>5                                                   10(22.2)                                   3(30)                                 
            **Lymph node status**                                                                                               1.176(0.281-4.926)       1.000
                  Negative                                                 12(30.8)                                  4(33.3)                                
                  Positive                                                 27(69.2)                                  10(37)                                 
           **Lymphatic invasion**                                                                                               1.077(0.281-4.127)       1.000
                  Negative                                                 18(47.4)                                  6(33.3)                                
                  Positive                                                 20(52.6)                                   7(35)                                 
            **Vascular invasion**                                                                                               2.292(0.511-10.284)      1.000
                  Negative                                                 13(32.5)                                  4(30.8)                                
                  Positive                                                 27(67.5)                                  10(37)                                 
        **Estrogen receptor status**                                                                                            0.357(0.075-1.704)       0.222
                  Negative                                                 8(17.4)                                    4(50)                                 
                  Positive                                                 38(82.6)                                 10(26.3)                                
       **Progesterone receptorstatus**                                                                                          0.938(0.265-3.313)       1.000
                  Negative                                                 22(48.9)                                  7(31.8)                                
                  Positive                                                23 (51.1)                                  7(30.4)                                
           **Her-2/neu receptor**                                                                                               1.061(0.285-3.948)       1.000
                  Negative                                                 30(65.2)                                   9(30)                                 
                  Positive                                                 16(34.2)                                  5(31.3)                                
                   **P53**                                                                                                      0.625(0.166-2.356)       0.526
                  Negative                                                23(53.50)                                  8(34.8)                                
                  Positive                                                 20(46.5)                                   5(25)                                 
            **Cancer metastasis**                                                                                               3.056(0.718-13.011)      0.191
                  Negative                                                 18(38.3)                                  3(16.7)                                
                  Positive                                                 29(61.7)                                 11(37.9)                                
        **Overall survival (5 yr%)**                                    18 of 41(43.9)                               3(16.7)    0.218(0.049-0.963)       0.051

^\*^OR; Odds ratio, (95% CI); confidence interval reflects a significance level of 0.05.

###### 

**Frequency of mtDNA*ATPase 6/8*gene sequence alterations in 49 breast cancer patients**

  **No**   **Locus**    **Allele**   **Nucleotide position**   **Nucleotide change**   **Amino acid change\***   **Mutation status\*\***   **Frequency**   **OR; 95% CI**^**\*\*\***^   ***P Value***   **Reference**
  -------- ------------ ------------ ------------------------- ----------------------- ------------------------- ------------------------- --------------- ---------------------------- --------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1        MT-ATPase8   A8384G       8384                      A-G                     **T7A**                   Hm                        1               1.021;0.980-1.063            0.315           NR^**\*\*\*\***^
  2        MT-ATPase6   T8542C       8542                      T-C                     **F6L**                   Hm                        1               1.021;0.980-1.063            0.315           NR
  3        MT-ATPase8   T8542C       8542                      T-C                     **C59C**                  Hm                        1               1.021; 0.980-1.063           0.315           NR
  4        MT-ATPase6   G8557A       8557                      G-A                     **A11T**                  Hm                        1               1.021; 0.980-1.063           0.315           Colonic crypts cancer \[[@B34]\], Breast cancer \[[@B27],[@B28]\]
  5        MT-ATPas8    G8557A       8557                      G-A                     L64L                      Hm                        1               1.021; 0.980-1.063           0.315           Alzheimer\'s disease \[[@B40]\]
  6        MT-ATPase6   T8567C       8567                      T-C                     **I14T**                  Hm                        1               1.021; 0.980-1.063           0.315           Parkinson\'s disease \[[@B42]\]
  7        MT-ATPas8    T8567C       8567                      T-C                     **S68P**                  Hm                        1               OR 1.021;: 0.980-1.063       0.315           Parkinson\'s disease \[49\]
  8        MT-ATPase6   G8572A       8572                      G-A                     **G16S**                  Hm                        1               OR 1.021; 0.980-1.063        0.315           Thyroid tumor \[50\]
  9        MT-ATPas8    G8572A       8572                      G-A                     **G69S**                  Hm                        1               1.021; 0.980-1.063           0.315           Colonic crypts cancer \[[@B34]\]
  10       MT-ATPase6   C8684T       8684                      C-T                     **T53I**                  Hm                        1               1.021; 0.980-1.063           0.315           Multiple Sclerosis \[51\], Ataxia telangiectasia \[[@B21]\], Huntington \[52\], Autism \[53\], Osteosarcoma \[54\],
  11       MT-ATPase6   T8697C       8697                      T-C                     **I24T**                  Hm                        1               1.021; 0.980-1.063           0.315           Thyroid tumor \[50\], Multiple Sclerosis \[51\], Ataxia telangiectasia \[[@B21]\], Breast cancer \[[@B30]\], Colorectal adenomatous polyps \[[@B40]\]
  12       MT-ATPase6   A8701G       8701                      A-G                     **T59A**                  Hm                        2               1.043; 0.984-1.105           0.153           Thyroid tumor \[50\], Ataxia telangiectasia \[[@B21]\], Breast cancer \[[@B27],[@B29]\], colorectal adenomatous polyps \[[@B38]\], Osteosarcoma \[54\]
  13       MT-ATPase6   T8777C       8777                      T-C                     F117F                     Hm                        1               1.021; 0.980-1.063           0.315           NR
  14       MT-ATPase6   C8794T       8794                      C-T                     **H90Y**                  Hm                        2               1.043; 0.984-1.105           0.153           Exercise Endurance/Coronary Atherosclerosis risk\[[@B32]\]
  15       MT-ATPase6   A8860G       8860                      A-G                     **T112A**                 Hm                        49                                           0.000           Colorectal cancer \[[@B36],[@B38]\], Ovarian cancer \[[@B37]\], Breast cancer \[[@B27],[@B29],[@B34]\], Human glioma cells \[[@B33]\], Osteosarcoma \[54\], Leber\'s hereditary optic neuropathy \[[@B35]\]
  16       MT-ATPase6   T8877C       8877                      T-C                     F117F                     Hm                        3               1.065; 0.992--1.114          0.079           Leber\'s hereditary optic neuropathy \[55\]
  17       MT-ATPase6   T8881C       8881                      T-C                     **S119P**                 Ht                        1               1.021; 0.980-1.063           0.315           NR
  18       MT-ATPase6   C8910T       8910                      C-T                     F128F                     Ht                        2               1.043; 95% CI: 0.984-1.105   0.153           The southern belt of Siberia population \[56\]
  19       MT-ATPase6   G8950A       8950                      G-A                     **V142I**                 Hm                        2               1.043; 0.984-1.105           0.153           Huntington \[54\],LDYT \[57\]
  20       MT-ATPase6   G8994A       8994                      G-A                     L156L                     Hm                        1               1.021; 0.980-1.063           0.315           Ataxia telangiectasia \[[@B21]\], Breast cancer \[[@B27]\], Colorectal adenomatous polyps \[[@B38]\]
  21       MT-ATPase6   C9003A       9003                      C-A                     R159R                     Hm                        1               OR 1.021; 0.980-1.063        0.315           NR
  22       MT-ATPase6   A9007G       9007                      A-G                     **T161A**                 Hm                        1               1.021; 0.980-1.063           0.315           Deafness associated \[58\]
  23       MT-ATPase6   A9041G       9041                      A-G                     **H172R**                 Hm                        1               1.021; 0.980-1.063           0.315           NR
  24       MT-ATPase6   G9055A       9055                      G-A                     **A177T**                 Hm                        3               1.065; 0.992--1.114          0.079           Colorectal cancer \[[@B36]\], Colorectal adenomatous polyps \[[@B38]\], Breast cancer \[[@B28],[@B30]\], Non-muscle invasive bladder cancer \[[@B44]\], Osteosarcoma \[54\], Pancreatic cancer \[[@B43]\], Parkinson\'s disease protective factor \[[@B45]\]
  25       MT-ATPase6   G9085A       9085                      C-T                     **P187S**                 Hm                        1               1.021; 0.980-1.063           0.315           NR
  26       MT-ATPase6   T9090C       9090                      T-C                     S188S                     Hm                        1               1.021; 0.980-1.063           0.315           Colorectal cancer \[59\] Leber\'s hereditary optic neuropathy \[60\]
  27       MT-ATPase6   T9148C       9148                      T-C                     L208L                     Hm                        1               1.021; 0.980-1.063           0.315           Occipital stroke \[61\]
  28       MT-ATPase6   C9168T       9168                      C-T                     F214F                     Hm                        1               1.021; 0.980-1.063           0.315           NR

Abbreviations:

\*Missense mutations are in bold.

\*\*Hm: Homoplasmic, Ht: Heteroplasmic.

\*\*\* OR; Odds ratio, (95% CI); confidence interval reflects a significance level of 0.05.

\*\*\*\*NR; Not reported in mitomap website.

Furthermore, the damaging impact of an amino acid substitution on the structure and function of the ATPase6 and 8 proteins was predicted using PolyPhen-2 software (Table [3](#T3){ref-type="table"}). The mtDNA variants A8384 (T7A), T8567C (I14T), G8572A (G16S), A9041G (H172R) and G9055A (A177T) showed significant effects on the resulting protein. However, there was no significant association between mtDNA alterations and the clinico-pathological characteristics of breast cancer patients.

###### 

**Impact of non-synonymous\* (coding) substitutions on*the ATPase6*and*8*genes**

  **Non-synonymous coding substitutions**   **Damaging score**   **Benign score**
  ----------------------------------------- -------------------- ------------------
  ***ATPase 6*gene**                                             
  **T8542C( F6L)**                          0.976                0.917
  G8557A (A11T)                             0.002                0.004
  T8567C (I14T)                             0.617                0.280
  G8572A (G16S)                             0.895                0.498
  C8684T (T53I)                             0.005                0.005
  A8701G (T59A)                             0.002                0.005
  C8794T (H90Y)                             0.002                0.003
  A8860G (T112A)                            0.000                0.003
  **T8881C (S119P)**                        0.325                0.149
  G8950A (V142I)                            0.000                0.001
  A9007G (T161A)                            0.994                0.988
  **A9041G H(172R)**                        0.854                0.331
  G9055A (A177T)                            0.854                0.331
  ***ATPase 8*gene**                                             
  A8384G (T7A)                              0.845                0.399
  T8542C (S68P)                             0.000                0.000

Non-synonymous variants were predicted as damaging and benign (With a score of 0 to 1) based on effects on the resulting protein using PolyPhen-2 software.

The new variants are in bold format.

Discussion
==========

The identification of mitochondrial DNA mutations and/or polymorphism patterns is rapidly developing in the field of molecular oncology. A large number of somatic mutations in the mitochondrial genome have been recently reported in different types of cancer,luding breast, colon and ovarian cancers \[[@B5],[@B6]\]. These molecular markers may have potential implication in cancer research.

Mitochondrial complex V genes play an important role in ATP production \[[@B25]\] and the apoptosis pathways \[[@B5]\]. The contribution of mtDNA complex V variants in cell transformation, elevated ROS production, and tumor progression has been described previously \[[@B26]\]. Moreover, efficient programmed cell death needs the molecular machinery of ATP synthase \[[@B27]\].

The *ATPase6* gene, one of the complex V genes, contributes to mtDNA maintenance \[[@B25]\]. Furthermore, the *ATPase8* variants have been detected in rat and human bladder cancer cells developed through chemically-induced carcinogenesis \[[@B28]\]. In a meta-analysis study carried out by Lu et al. a total of 55 variants, comprising 34 missense variants, 20 silent variants and 1 nonsense variant, were found in the *ATPase6* gene and a total of 9 variants, including 2 missense variants and 7 silent variants, were detected in the *ATPase8* gene \[[@B6]\].

In our study, among 28 distinct somatic variants, 18 were missense variants. Six variants have been previously reported in breast cancer \[[@B29]-[@B32]\] and 9 variants were new, including 4 missense and 5 silent variants which were observed for the first time in breast cancer patients. However, 17 variants were previously reported in other types of cancers and diseases (Table [2](#T2){ref-type="table"}). In addition, more non-synonymous amino acid changing variants were found in the *ATPase6* gene in comparison with the *ATPase8* gene (Table [2](#T2){ref-type="table"}). Our findings suggest that in breast cancer patients, the *ATPase6* gene might be more susceptible to mutation in comparison to the *ATPase8* gene. Shidara et al. and Kirches reported that *ATPase6* gene variants may enhance cancer progression by preventing apoptosis pathways \[[@B6],[@B33]\].

The functional role of *ATPase6/8* variants in tumorigenesis is debatable; however, some of these variants are located in structurally and functionally important regions of the proteins. For instance, the A8860G alteration in *ATPase6* has been reported as a polymorphism in different studies \[[@B29],[@B31],[@B34]-[@B40]\]. The frequency of this polymorphism has been reported to be from 79--91.66% in breast cancer patients \[[@B30],[@B31]\], 75-100% in other types of cancers \[[@B38]-[@B40]\] and 92.85%-100% in neurodegenerative diseases \[[@B37],[@B41]-[@B43]\]. Our results indicated that the A8860G variant was present in 100% of tumor tissue samples. Although this variant is located in a poorly conserved protein region with no impact on protein structure based on PolyPhen-2 software (Table [3](#T3){ref-type="table"}), the variation may still contribute to other mtDNA and nDNA mutations.

The frequency of the G9055A variation has been reported as either 10.5% \[[@B28]\] or 18.6% \[[@B30]\] in breast cancer patients, indicating that it may increase the risk of breast cancer progression (OR: 3.03, 95% CI: 1.63-5.63, *P* = 0.0004) \[[@B32],[@B44]\]. This variation is located in a conserved protein region with damaging impact on protein structure (Table [3](#T3){ref-type="table"}). Furthermore, the frequency of this polymorphism has been reported as 10% in pancreatic cancer \[[@B45]\] and as 57% and 100% in tubular and villous adenomas, respectively \[[@B40]\]. Moreover, the high frequency of this variation has been shown in non-muscle invasive bladder cancer \[[@B46]\]. In addition, this polymorphism has been reported as a protective factor (OR: 0.46, 95% CI: 0.22-0.91, *P* = 0.03) in Caucasian women with Parkinson's disease \[[@B47]\]. From these results, we propose that this mtDNA variation is unfavorable for neurodegenerative disorders, while having a protective effect on cancer. According to our results, the frequency of this variation was 6.12% (3 of 49) in tumor samples.

A study by Petros et al. indicated that T8993G in *ATPase6* can contribute to tumor growth in nude mice \[[@B48]\]. Another study showed that cybrids with a T8993G or T9176 *ATPase6* mutation in nude mice can contribute to tumor development by preventing apoptosis in the early stages of tumor growth \[[@B10]\]. However, we detected none of these mutations in breast cancer patients.

Based on our results, the existence of more than one missense variants in some cases with different clinico-pathological features (Table [4](#T4){ref-type="table"}) suggests a synergistic effect of different mtDNA variations on carcinogenesis.

###### 

MtDNA alterations and clinico-pathological characteristics of breast cancer patients with more than one missense mutation

  **Case**    **Locus**    **Variant**   **Frequency**   **Age (Yrs)**   **Grade**   **Tumor size (cm)**   **TNM\***   **Stage**
  ----------- ----------- ------------- --------------- --------------- ----------- --------------------- ----------- -----------
  BC-6        *ATPase6*      A8384G            4              44            III               3             T2N1M0        II
  T8542C                                                                                                              
  *ATPase8*   T8542C                                                                                                  
  A8860G                                                                                                              
  BC-10       *ATPase6*      A8860G            3              55            III              2.5            T2N0M1        IV
  G8950A                                                                                                              
  A9041G                                                                                                              
  BC-19       *ATPase6*      A8860G            2              42            II                5             T3N2M1        IV
  G9055A                                                                                                              
  BC-20       *ATPase6*      A8860G            2              68            III              1.8            T2N1M1        IV
  A9007G                                                                                                              
  BC-21       *ATPase6*      A8860G            2              43                             1.2            T1NXM1        IV
  G8950A                                                                                                              
  BC-23       *ATPase6*      A8860G            2              36            III              10             T3N3M1        IV
  G9055A                                                                                                              
  BC-25       *ATPase6*      A8860G            2              50            II               13             T4N3M1        IV
  C8794T                                                                                                              
  BC-32       *ATPase6*      A8860G            2              74             I                5             T3N1M1        IV
  T8881C                                                                                                              
  BC-35       *ATPase6*      C8794T            2              75            II                5             T3N3M1        IV
  A8860G                                                                                                              
  BC-37       *ATPase6*      A8860G            2              67            II                2             T1N0M0         I
  G9095A                                                                                                              
  BC-38       *ATPase6*      A8701G            3              69            II               3.5            T2N3M1        IV
  A8860G                                                                                                              
  T9085C                                                                                                              
  BC-39       *ATPase6*      A8701G            2              59            III               3             T2N0M0        II
  A8860G                                                                                                              
  BC-41       *ATPase6*      C8684T            2              51            II               3.5            T2N0M1        IV
  A8860G                                                                                                              
  BC-48       *ATPase6*      T8567C            3              41            II               4.5            T2N3M1        IV
              *ATPase8*      T8567C                                                                                         
                             A8860G                                                                                         

T1--T4: Size and/or extent of the primary tumor; NX: Regional lymph nodes cannot be evaluated; N0: No regional lymph node involvement (no cancer found in the lymph nodes); N1-N3:Involvement of regional lymph nodes (number and/or extent of spread); M0:No distant metastasis; M1:Distant metastasis (spread of cancer from one part of the body to another). There was no significant association between the mtDNA alterations and clinic-pathological characteristics of breast cancer patients.

In conclusion, the high frequency of *ATPase6* gene alterations in breast cancer proposes that mitochondrial gene variants may play an important role in tumorigenesis, changing the energy metabolism in cancer cells, and may be suggested as molecular biomarkers in breast cancer.
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